Reports
Sale
Ischemia Reperfusion Injury Therapeutics Market Size, Share: By Treatment Type: Drug Therapy, Medicated Gases, Others; By Indications: Heart Injury, Kidney Injury, Intestine Injury, Others; By Route of Administration: Oral, Parenteral, Topical, Inhalation; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Ischemia Reperfusion Injury Therapeutics Market Outlook
The ischemia reperfusion injury therapeutics market size was valued at USD 1.67 billion in 2023, driven by the prevalence of chronic diseases in a geriatric population across the globe. The market is expected to grow at a CAGR of 4.6% during the forecast period of 2024-2032, with the values likely to rise from USD 1.75 billion in 2024 to USD 2.51 billion by 2032.
Ischemia Reperfusion Injury Therapeutics: Introduction
Ischemia reperfusion injury, also known as reperfusion injury or reoxygenation injury, occurs when blood supply returns to an ischemic area, leading to sudden tissue death. Instead of facilitating normal function in the cell, the restoration of oxygen and nutrients leads to inflammation and oxidative damage.
Ischemia Reperfusion Injury Therapeutics Market Analysis
Ischemia-reperfusion injury is a major cause of multi-organ malfunction post a severe trauma with heavy bleeding. IRI occurrence may also lead to severe cardiac, pulmonary, spinal cord renal, hepatic and limb problems. Hence, the ischemia-reperfusion injury therapeutics market demand has increased.
Metformin, a plant-based anti-hyperglycemic drug having multiple mechanisms of action, has been a common ischemia reperfusion injury drug. It modulates ROS (reactive oxygen species) levels and oxidative damage during reperfusion, preventing organ malfunction. Focusing on kidney transplantation, Treprostinil (Remodulin) is another antihypertensive agent which is formulated as an injectable solution, also being considered for the treatment of ischemia-reperfusion injury.
With the emergence of nanotechnology in the medical field and a better understanding of cell interactions, scientists have diverted towards applying nanoparticle-mediated medicine. It can be considered an effective therapy owing to its enhanced drug accumulation, reduced systemic toxicity and improved pharmacokinetics. Numerous biomaterials like microneedles, liposomes, cardiac patches, and hydrogels are being explored as a potential tool for treatment. Given the substantial research efforts dedicated to this area, the ischemia-reperfusion injury therapeutics market value is estimated to rise significantly during the forecast period.
Ischemia Reperfusion Injury Therapeutics Market Segmentation
Market Breakup by Treatment Type
- Drug Therapy
- Antioxidants
- Anti-Inflammatory Agents
- Vasodilators
- Immunomodulators
- Others
- Medicated Gases
- Others
Market Breakup by Indications
- Heart Injury
- Kidney Injury
- Intestine Injury
- Other Injury
Market Breakup by Route of Administration
- Oral
- Parenteral
- Topical
- Inhalation
Market Breakup by End User
- Hospitals and Clinics
- Ambulatory Surgical Centres
- Research Institutes
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region– 7MM
- United States
- EU-4 and the United Kingdom
- Japan
Ischemia Reperfusion Injury Therapeutics Market Overview
Cardiovascular diseases continue to be some of the most chronic diseases worldwide, still affecting the lives of millions. Myocardial ischemia-reperfusion accounts for approximately 1.72% of deaths and disabilities in the global population. With the prevalence of cardiovascular, neurological, and kidney-related diseases, North America has held a significant part of the ischemia-reperfusion injury therapeutics market share in the historic period. A technologically advanced infrastructure, rising research and developments in medical care facilities and capital investments are key factors accountable for the market size.
The Asia Pacific region is expected to witness exponential growth in the coming years owing to the presence of a geriatric population that may lead to an increased incidence of chronic diseases like myocardial infarction. Moreover, the government initiatives to build technology-supportive infrastructure, an influx of foreign funds due to the easy availability of resources and the emergence of healthcare startups, can bring some substantial innovations in the ischemia reperfusion injury therapeutics market.
Ischemia Reperfusion Injury Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- AstraZeneca PLC
- Novartis International AG
- Merck & Co., Inc.
- Johnson & Johnson
- Bayer AG
- Sanofi SA
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Amgen Inc.
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- Regeneron Pharmaceuticals, Inc.
- Mitsubishi Tanabe Pharma Corporation
- Grifols, S.A.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Indications |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region-7MM |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ischemia Reperfusion Injury Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ischemia Reperfusion Injury Epidemiology Analysis- 7MM
5.1 Epidemiology Overview (2016-2031)
5.2 United States Ischemia Reperfusion Injury Epidemiology (2016-2031)
5.3 EU-4 and United Kingdom Ischemia Reperfusion Injury Epidemiology (2016-2031)
5.4 Japan Ischemia Reperfusion Injury Epidemiology (2016-2031)
6 Ischemia Reperfusion Injury Therapeutics Market Overview
6.1 Ischemia Reperfusion Injury Therapeutics Market Historical Value (2017-2023)
6.2 Ischemia Reperfusion Injury Therapeutics Market Forecast Value (2024-2032)
7 Ischemia Reperfusion Injury Therapeutics Market Landscape
7.1 Ischemia Reperfusion Injury Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ischemia Reperfusion Injury Therapeutics: Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Indications
7.2.3 Analysis by Route of Administration
8 Ischemia Reperfusion Injury Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ischemia Reperfusion Injury Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Ischemia Reperfusion Injury Therapeutics Market Segmentation
11.1 Ischemia Reperfusion Injury Therapeutics Market by Treatment Type
11.1.1 Market Overview
11.1.2 Drug Therapy
11.1.2.1 Antioxidants
11.1.2.2 Anti-Inflammatory Agents
11.1.2.3 Vasodilators
11.1.2.4 Immunomodulators
11.1.2.5 Others
11.1.3 Medicated Gases
11.1.4 Others
11.2 Ischemia Reperfusion Injury Therapeutics Market by Indications
11.2.1 Market Overview
11.2.2 Heart Injury
11.2.3 Kidney Injury
11.2.4 Intestine Injury
11.2.5 Other Injury
11.3 Ischemia Reperfusion Injury Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Topical
11.3.5 Inhalation
11.4 Ischemia Reperfusion Injury Therapeutics Market by End User
11.4.1 Market Overview
11.4.2 Hospitals and Clinics
11.4.3 Ambulatory Surgical Centres
11.4.4 Research Institutes
11.4.5 Others
11.5 Ischemia Reperfusion Injury Therapeutics Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.5.5 Others
11.6 Ischemia Reperfusion Injury Therapeutics Market by Region– 7MM
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.4 Japan
12 United States Ischemia Reperfusion Injury Therapeutics Market
12.1 U.S. Ischemia Reperfusion Injury Therapeutics Market Historical Size (2017-2023)
12.2 U.S. Ischemia Reperfusion Injury Therapeutics Market Forecast Size (2024-2032)
12.3 Market Size by Therapeutic Class
13 EU-5 and the United Kingdom Ischemia Reperfusion Injury Therapeutics Market
13.1 EU-5 and the United Kingdom Ischemia Reperfusion Injury Therapeutics Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Ischemia Reperfusion Injury Therapeutics Market Forecast Size (2024-2032)
13.3 Market Size by Therapeutic Class
14 Japan Ischemia Reperfusion Injury Therapeutics Market
14.1 Japan Ischemia Reperfusion Injury Therapeutics Market Historical Size (2017-2023)
14.2 Japan Ischemia Reperfusion Injury Therapeutics Market Forecast Size (2024-2032)
14.3 Market Size by Therapeutic Class
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Pfizer Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 AstraZeneca PLC
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Novartis International AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Merck & Co., Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Johnson & Johnson
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Bayer AG
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Sanofi SA
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 GlaxoSmithKline plc
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Boehringer Ingelheim International GmbH
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Bristol-Myers Squibb Company
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 AbbVie Inc.
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Amgen Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Gilead Sciences, Inc.
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 F. Hoffmann-La Roche Ltd.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Eli Lilly and Company
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
21.16 Takeda Pharmaceutical Company Limited
21.16.1 Financial Analysis
21.16.2 Product Portfolio
21.16.3 Demographic Reach and Achievements
21.16.4 Mergers and Acquisitions
21.16.5 Certifications
21.17 Biogen Inc.
21.17.1 Financial Analysis
21.17.2 Product Portfolio
21.17.3 Demographic Reach and Achievements
21.17.4 Mergers and Acquisitions
21.17.5 Certifications
21.18 Regeneron Pharmaceuticals, Inc.
21.18.1 Financial Analysis
21.18.2 Product Portfolio
21.18.3 Demographic Reach and Achievements
21.18.4 Mergers and Acquisitions
21.18.5 Certifications
21.19 Mitsubishi Tanabe Pharma Corporation
21.19.1 Financial Analysis
21.19.2 Product Portfolio
21.19.3 Demographic Reach and Achievements
21.19.4 Mergers and Acquisitions
21.19.5 Certifications
21.20 Grifols, S.A.
21.20.1 Financial Analysis
21.20.2 Product Portfolio
21.20.3 Demographic Reach and Achievements
21.20.4 Mergers and Acquisitions
21.20.5 Certifications
22 Ischemia Reperfusion Injury Therapeutics - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1.67 billion in 2023, driven by incidence of chronic illnesses in an ageing population across the globe.
The market is anticipated to grow at a CAGR of 4.6% during the forecast period of 2024-2032, likely to reach a market value of USD 2.51 billion by 2032.
The growth of the market can be attributed to the pharmaceutical and technical advances in the therapeutics, owing to the prevalence of chronic cardiovascular, neurological, and kidney-related diseases, with an aim to prevent multi-organ malfunction that may occur due to IRI.
Nanoparticle-mediated medicine has emerged in the market to treat IRI. Several biomaterials like microneedles, liposomes, cardiac patches, and hydrogels are also being explored as a potential tool for treatment.
The major regions of the market include the United States, Japan, EU-4, and the United Kingdom.
The major treatment methods in the market include drug therapy and medicated gases, among others. Drug therapy is further categorised into antioxidants, anti-inflammatory agents, vasodilators, and immunomodulators, among others.
Heart, kidney, intestine, and other injuries are some of the key indications.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The route of administration can be divided into oral, parenteral, topical or inhalation.
Major end users include hospitals, clinics, ambulatory surgical centres, and research institutes, among others.
Key players involved in the market are Pfizer Inc., AstraZeneca PLC, Novartis International AG, Merck & Co., Inc., Johnson & Johnson, Bayer AG, Sanofi SA, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Regeneron Pharmaceuticals, Inc., Grifols, S.A., and Mitsubishi Tanabe Pharma Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER